ea0011p746 | Steroids | ECE2006
Morelli A
, Filippi S
, Mancina R
, Vignozzi L
, Vannelli GB
, Ambrosini S
, Crescioli C
, Donati S
, Adorini L
, Maggi M
BXL-628 is a non-hypercalcemic calcitriol analog successfully tested in a phase IIa trial for benign prostate hyperplasia therapy. Because part of low urinary tract symptoms (LUTS) are generated by overactive bladder (OAB) and bladder expresses the calcitriol receptor (VDR), we investigated the BXL-628 effects on bladder contractility and RhoA/ROK signalling activated in OAB, by in vivo (2-weeks; 30 mcg/Kg, Sprague-Dawley, SD, and spontaneously hypertensive rats, SHR) a...